



Next-Generation Interventions for *Clostridioides difficile* Infections to Minimize Microbiota Disturbance, Increase Efficacy, and Decrease Recurrence

Guest Editors:

Prof. Dr. Wen-Chien Ko

Department of Medicine,
National Cheng Kung University,
Tainan, Taiwan

Dr. Yuan-Pin Hung

Department of Internal Medicine,
Tainan Hospital, Ministry of
Health and Welfare, Tainan,
Taiwan

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editors

Dear Colleagues,

Clostridioides difficile is the major cause of community- and healthcare-associated infections, ranging from mild diarrhea to pseudomembranous colitis or toxic megacolon. Among patients with *C. difficile* infection (CDI), oral vancomycin or fidaxomicin has been suggested for either mild–moderate or severe CDI. Nevertheless, oral anti-*C. difficile* antibiotics, such as vancomycin, markedly disrupt the intestinal microbiota and lead to prolonged loss of colonization resistance to CDI.

Therefore, we welcome the submission of interdisciplinary work and collaborative research. Original research articles, literature review, or meta-analyses that are relevant to treat CDIs are greatly encouraged.

Keywords: *Clostridioides difficile* infection; Vancomycin; Fidaxomicin; Probiotics; Fecal microbiota transplantation; Microbiota; Metabolome; Recurrence





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi